Linerixibat reduces cholestatic pruritus in patients with primary biliary cholangitis

This publication has 11 references indexed in Scilit:

• Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
  The Lancet Gastroenterology & Hepatology, 2025
• Effectiveness of Nemolizumab for Refractory Pruritus in a Pediatric Patient With Atopic Dermatitis After Biliary Atresia Surgery
  Cureus, 2025
• Upadacitinib for refractory primary biliary cholangitis
  Journal of Hepatology, 2025
• Relationship between pruritus and sleep in participants with primary biliary cholangitis in the Phase 2b GLIMMER trial
  Journal of Patient-Reported Outcomes, 2024
• Dupilumab treatment for cholestatic pruritus
  Dermatologic Therapy, 2022
• Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial
  The Lancet Gastroenterology & Hepatology, 2018
• Reconstituted high‐density lipoprotein can elevate plasma alanine aminotransferase by transient depletion of hepatic cholesterol: role of the phospholipid component
  Journal of Applied Toxicology, 2015
• Benign elevations in serum aminotransferases and biomarkers of hepatotoxicity in healthy volunteers treated with cholestyramine
  BMC Pharmacology and Toxicology, 2014
• Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence
  Hepatology, 2006
• Bezafibrate treatment: a new medical approach for PBC patients?
  Journal of Gastroenterology, 2003